Survivors of Childhood Cancer Risk Premature Menopause

A woman who survives cancer as a child has a greatly increased risk of experiencing menopause before she reaches age 40. If this occurs, her risk for osteoporosis, cardiac disease, and psychosexual dysfunction increases.



Researchers working with the Childhood Cancer Survivors Study (CCSS), a retrospective longitudinal cohort study of more than 20,000 childhood cancer survivors diagnosed between 1970 and 1986, found that survivors had nonsurgical premature menopause at a rate 13 times greater than the control group. The affected women were older at time of assessment, more likely to have had Hodgkin lymphoma, less likely to have had leukemia, and had greater ovarian exposure to radiation and/or alkylating chemotherapy agents.



Dr. Charles A. Sklar of Memorial Sloan-Kettering Cancer Center and colleagues identified 2,819 CCSS subjects who were menstruating more than 5 years after their cancer diagnosis; controls were selected from among survivors' siblings, not always from the same families - in this case 1,065 age-matched women with normal menstrual patterns.



In an accompanying editorial in the July 5 Journal of the National Cancer Institute (JNCI), Drs. Wendy Y. Chen and JoAnn E. Manson of Harvard Medical School wrote, "the health consequences of premature menopause are still poorly understood," noting that some of them are controversial, and not all are negative: such women have a lower risk of breast and ovarian cancer. Nonetheless, this study helps clinicians identify women for whom counseling, prevention, screening, and treatment strategies should be considered. NCI Bulletin 7/11/2006

Blog Category: 

More Articles

More Articles

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

In a large trial of older, newly diagnosed patients with chronic lymphocytic leukemia (CLL),...

Today’s typical treatments have been unable to cure numerous types of lymphoma, but emerging immunotherapies could provide the key to...

Biotech firm Gilead Sciences Inc. has announced that the first patient has been dosed in a Phase III trial evaluating the safety and efficacy of...

Last week at the 54th American Society of Hematology Annual Meeting and Exposition in Atlanta, researchers out of MD Anderson Cancer Center in...

The results of a pair of long-term survival studies indicate the therapeutic value of BEXXAR (...

A new lab test that can improve survival rates among patients with chronic lymphocytic leukemia (...

Aggressive Non-Hodgkin’s Lymphomas (NHLs) are fast growing cancers (as opposed to indolent cancers). They involve...

A B cell is a type of lymphocyte that produces antibodies to fight infections. These are the most prevalent lymphocytes in the bloodstream and are...

Sitemap